Dr. Lyman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
210 MARKET STREET
Suite 303
Kirkland, WA 98033Phone+1 919-724-0038Fax+1 919-724-0038- Is this information wrong?
Summary
- Previously Director of Comparative Effectiveness Research at the Duke Cancer Institute & Senior Fellow Duke Center for Clinical Health Policy Research. Received undergraduate and medical degree from SUNY Buffalo, Internal Medicine residency at UNC Chapel Hill, Clinical Hematology/Oncology Fellowship at Roswell Park and Postdoctoral Fellowship in Biostatistics at the Harvard School of Public Health & Dana Farber Cancer Center. Previously Professor of Medicine and Chief of Medicine at the Moffitt Cancer Center as well as Prof of Epidemiology/Biostatistics and Associate Chair Medicine at USF. Held Thomas Ordway Endowed Chair & Cancer Center Director Albany Medical College & Prof Epidemiology/Biostatistics SUNY Albany and Prof of Medicine, Associate Cancer Center Director and Director of Health Services and Outcomes Research at University of Rochester. Currently Executive Officer for the SWOG Cancer Research Network. Fellow of ASCO, the American College of Physicians, and the Royal College of Physicians. Editor-In-Chief of Cancer Investigation and on Editorial Board of several oncology specialty journals. Serves on Board of Directors of the Hope Foundation for Cancer Research. Dr Lyman states "I have been extremely privileged to work with some of worlds best biostatisticians/trialists over years including postdoctoral for the fellowship with Prof Marvin Zelen at Harvard, Visiting Prof with Prof Stuart Pocock at London School of Hygiene &Tropical Medicine & Prof Doug Altman at Centre for Health Statistics at Oxford now in Public Health Sciences at Fred Hutch enabling my listing among the top 1% of most highly cited investigators by Web of Science for 6 consecutive years with over 90,000 citations. Thank you all.
Education & Training
- Harvard School of Public HealthPost-Doctoral Fellowship, Biostatistics, 1981 - 1982
- University at BuffaloFellowship, Hematology and Medical Oncology, 1974 - 1977
- University of North Carolina HospitalsResidency, Internal Medicine, 1972 - 1974
- Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1972
Certifications & Licensure
- NC State Medical License 1972 - 2025
- WA State Medical License 2014 - 2025
- NY State Medical License 1974 - 2009
- FL State Medical License 1977 - 2002
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Distinguished Emeritus Member American Society of Hematology, 1976-2023
- America's Top Doctors Castle Connolly, 2005-2015
- America's Top Doctors for Cancer Castle Connolly, 2005-2015
- Join now to see all
Clinical Trials
- A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients Start of enrollment: 2009 Jul 01
Publications & Presentations
PubMed
- Drug development for major chronic health conditions-aligning with growing public health needs: Proceedings from a multistakeholder think tank.Konstantin A Krychtiuk, Tomas Lg Andersson, Ulrike Bodesheim, Javed Butler, Lesley H Curtis, Mitchell Elkind, Adrian F Hernandez, Christoph Hornik, Gary H Lyman, Pooja...> ;American Heart Journal. 2024 Apr 1
- The Nature, Origin, and Evolution of Life: Part V Bringing It Together: Concepts, Constraints, and Closure.Lyman, C., Lyman, G., Kuderer, N.> ;Cancer Investigation. 2024 Feb 1
- 1 citationsThe Nature, Origin, and Evolution of Life: Part IV Cellular Differentiation and the Emergence of Multicellular Life.Lyman, C., Lyman, G., Kuderer, N.> ;Cancer Investigation. 2024 Jan 4
- Join now to see all
Journal Articles
- Aligning Cancer Clinical Trials with Cancer BurdenNicole M Kuderer, Gary H Lyman, JAMA Oncology
- Association of Generic Imatinib Availability and Pricing with Trends in Tyrosine Kinase Inhibitor Use in Patients with Chronic Myelogenous LeukemiaGary Lyman, MD, JAMA Oncology
Abstracts/Posters
- Health Care Costs Associated with Contemporary Chronic Myelogenous Leukemia (CML) Therapy Compared to Other Hematologic Malignancies (HEM)Gary H. Lyman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer Associated ThrombosisGary H. Lyman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Mental Health Screening in a Pediatric Sickle Cell Disease Clinic: Acceptability and Impact on Mental Health Discussions, Referrals, and Patient SatisfactionGary H. Lyman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
- Risk of Chemotherapy-Induced Febrile Neutropenia in Intermediate-Risk Regimens: Clinical and Economic Outcomes of Granulocyte Colony-Stimulating Factor ProphylaxisFebruary 1st, 2023
- Conquer Cancer Announces 2023 Genitourinary Cancers Symposium Merit AwardsJanuary 26th, 2023
- Cancer Treatment: The Side Effects of Chemotherapy - and How to Treat ThemNovember 18th, 2022
- Join now to see all
Professional Memberships
- Fellow
- Member
- Member
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: